Camurus reports positive topline results for CAM2056, semaglutide monthly depot

CAM2056 showed weight and A1c reductions comparable to or exceeding those seen for weekly semaglutide (Wegovy®) Results include a 9.3% weight reduction with CAM2056 vs. 5.2% with weekly semaglutide at Day 85 Safety and tolerability were consistent with weekly semaglutide CAM2056 has potential for monthly dosing with rapid initiation

LUND, Sweden, Nov. 10, 2025 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced positive topline results from a randomized, active-controlled Phase 1b study evaluating CAM2056, the company's monthly FluidCrystal® semaglutide formulation, in comparison to weekly semaglutide (Wegovy®)1 in 80 individuals with overweight or obesity. The study showed that CAM2056, given as two biweekly initiation doses followed by two monthly doses, was well tolerated, up to the highest initiation dose, and significantly reduced body weight, hemoglobin A1c (A1c), and fasting glucose in a dose-dependent manner. The reductions were comparable to or exceeded those with weekly semaglutide dosed according to prescribing information1.

"We are very pleased with the Phase 1b data showing that CAM2056 is well tolerated and achieves dose-dependent reductions in body weight and A1c, matching or exceeding those observed with weekly semaglutide," says Fredrik Tiberg, President & CEO, CSO of Camurus. "The study data suggest that CAM2056 allows rapid dose titration without compromising tolerability, whilst also allowing convenient monthly dosing. Further evaluation of CAM2056 is planned in an upcoming Phase 2b study."

CAM2056 is a monthly subcutaneous semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist formulated with Camurus' proprietary FluidCrystal® technology.

Topline results from the Phase 1b study include:

CAM2056 achieved a similar maximum plasma concentration (Cmax) at a four times higher monthly dose compared to weekly semaglutide. Additionally, CAM2056 showed longer time to Cmax and an extended-release profile suitable for monthly dosing. CAM2056 provided dose-dependent reductions in body weight, A1c and fasting glucose, comparable to or exceeding those with weekly semaglutide to end of treatment, Day 85 The mean weight change from baseline to Day 85 for CAM2056 10 mg was -9.3% compared to -5.2% for weekly semaglutide dosed as per prescribing information. The treatment difference was -4.1% (-7.1%, -1.1%), p=0.008. CAM2056 reached similar weight reduction after 3 months as weekly semaglutide after 5 months. The mean A1c change from baseline to Day 85 was -0.44%, after the last 10 mg dose. The treatment difference between CAM2056 and weekly semaglutide was -0.32% (-0.50%, -0.14%), p